Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program - 11/02/19
Doi : 10.1016/j.jaad.2018.10.052
Ryan C. Kelm, BS a, Erika L. Hagstrom, MD a, Regine J. Mathieu, BS a, Kelsey A. Orrell, MB, BCh, BAO a, Linda Serrano, MD a, Kelly A. Mueller, BS a, Anne E. Laumann, MBChB, MRCP (UK) a, Dennis P. West, PhD a, b, Beatrice Nardone, MD, PhD a, ⁎ 
a Department of Dermatology, Northwestern University, Chicago, Illinois
b Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
∗Correspondence to: Beatrice Nardone, MD, PhD, 676 N St. Clair St, Ste 1600, Chicago, IL 60611676 N St. Clair St, Ste 1600ChicagoIL60611
| Funding sources: Northwestern Medicine Enterprise Data Warehouse is supported by the National Institutes of Health's National Center for Advancing Translational Sciences (grant number UL1TR001422). |
|
| Conflicts of interest: None disclosed. |
|
| Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 3
P. 820-821 - mars 2019 Retour au numéro
Article précédent
- Sunburn prevalence among US adults, National Health Interview Survey 2005, 2010, and 2015
- Dawn M. Holman, Helen Ding, Zahava Berkowitz, Anne M. Hartman, Frank M. Perna
- The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa lesions
- Paul Leiphart, Heather Ma, Haley B. Naik, Joslyn S. Kirby
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?